D. Rischin et al., Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer, J CL ONCOL, 19(2), 2001, pp. 535-542
Purpose: To determine the maximum-tolerated dose of tirapazamine when combi
ned with cisplatin and radiation in patients with T3/4 and/or N2/3 squamous
cell carcinoma of the head and neck.
Patients and Methods: The starting schedule was conventionally fractionated
radiotherapy (70 Gy in 7 weeks) with concomitant cisplatin 75 mg/m(2) and
tirapazamine 290 mg/m(2) (before cisplatin) in weeks 1, 4, and 7 and tirapa
zamine alone 160 mg/m(2) three times a week in weeks 2, 3, 5, and 6. Positr
on emission tomography scans for tumor hypoxia (F-18 misonidazole) were per
formed before and during radiotherapy.
Results: We treated 16 patients with predominantly oropharyngeal primary tu
mors, including 10 patients with T4 or N3 disease. Febrile neutropenia occu
rred toward the end of radiotherapy in three out of six patients treated on
the initial dose level. Two of these patients also developed grade 4 acute
radiation reactions. Another 10 patients were treated with the same doses,
but the week 5 and week 6 tirapazamine doses were omitted. This resulted i
n less neutropenia and only one dose-limiting toxicity (DLT) (febrile neutr
openia), and eight out of 10 patients completed treatment without any dose
omissions. In these 10 patients, the acute radiation toxicities were not ob
viously enhanced compared with chemoradiotherapy regimens using concurrent
platinum and fluorouracil. F-18 misonidazole scans detected hypoxia in 14 o
f 15 patients at baseline, with only one patient having detectable hypoxia
at the end of treatment. With a median follow-up of 2.7 years, the 3-year f
ailure-free survival rate was 69%(SE, 12%), the 3-year local progression-fr
ee rate was 88% (SE, 8%), and the 3-year overall survival rate was 69% (SE,
12%).
Conclusion: DLT was due unexpectedly to febrile neutropenia, which could be
overcome by omitting tirapazamine in weeks 5 and 6. The combination of tir
apazamine, cisplatin, and radiotherapy resulted in remarkably good and dura
ble clinical responses in patients with very advanced head and neck cancers
. It warrants further investigation. J Clin Oncol 19:535-542. (C) 2001 by A
merican Society of Clinical Oncology.